HeartBeam (NASDAQ:BEAT – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations and price targets for HeartBeam and Bullfrog AI, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HeartBeam | 1 | 2 | 4 | 1 | 2.63 |
| Bullfrog AI | 1 | 0 | 0 | 0 | 1.00 |
HeartBeam currently has a consensus target price of $4.83, indicating a potential upside of 394.21%. Given HeartBeam’s stronger consensus rating and higher possible upside, research analysts clearly believe HeartBeam is more favorable than Bullfrog AI.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| HeartBeam | N/A | -844.01% | -412.88% |
| Bullfrog AI | N/A | -273.24% | -208.55% |
Risk & Volatility
HeartBeam has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -3, suggesting that its share price is 400% less volatile than the S&P 500.
Valuation and Earnings
This table compares HeartBeam and Bullfrog AI”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HeartBeam | N/A | N/A | -$21.01 million | ($0.62) | -1.58 |
| Bullfrog AI | $120,000.00 | 62.88 | -$6.50 million | ($0.63) | -0.95 |
Bullfrog AI has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
7.8% of HeartBeam shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 25.2% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
HeartBeam beats Bullfrog AI on 7 of the 13 factors compared between the two stocks.
About HeartBeam
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
